"id","instanceType","rationale","versionIdentifier","uuid:ID"
"StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","dc658fb2-3422-47c7-a867-b8736a366b08"
